AN2 Therapeutics, Inc. (ANTX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-10

AN2 Therapeutics, Inc. (ANTX) has filed 5 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-10. 3 Form 8-K material event filings were reported by ANTX in the last 90 days. InsiderAlpha tracks every ANTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About AN2 Therapeutics, Inc. (ANTX)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001880438

90-Day SEC Filing Activity

Form 4 filings (90d)	5
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-07-10

Recent ANTX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-10	Aziz Kabeer	Insider	A — Grant or award	2.9K	$0.00	—	SEC
2026-07-10	Martin Patricia A.	Insider	A — Grant or award	766	$0.00	—	SEC
2026-07-10	Marks Gilbert Lynn	Insider	A — Grant or award	2.8K	$0.00	—	SEC
2026-07-08	Eizen Joshua M	See Remarks	S — Open-market sale	5.9K	$4.17	$25K	SEC
2026-05-29	Williams Sarah Joanne	Principal Accounting Officer	S — Open-market sale	265	$4.43	$1K	SEC
2026-04-10	Aziz Kabeer	Insider	A — Grant or award	3.8K	$0.00	—	SEC
2026-04-10	Martin Patricia A.	Insider	A — Grant or award	1.2K	$0.00	—	SEC
2026-04-10	Marks Gilbert Lynn	Insider	A — Grant or award	3.8K	$0.00	—	SEC
2026-03-03	Williams Sarah Joanne	Principal Accounting Officer	S — Open-market sale	327	$1.06	$347	SEC
2026-02-20	Chanda Sanjay	Chief Development Officer	A — Grant or award	38.0K	$0.00	—	SEC
2026-02-20	Eizen Joshua M	See Remarks	A — Grant or award	50.0K	$0.00	—	SEC
2026-02-20	Day Lucy	Chief Financial Officer	A — Grant or award	38.0K	$0.00	—	SEC
2026-02-20	Williams Sarah Joanne	Principal Accounting Officer	A — Grant or award	48.4K	$0.00	—	SEC
2026-02-20	Easom Eric	Chief Executive Officer	A — Grant or award	112.2K	$0.00	—	SEC
2026-01-12	Marks Gilbert Lynn	Insider	A — Grant or award	11.6K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for AN2 Therapeutics, Inc. (ANTX). Updated in real time as new filings are submitted to the SEC.

Most-Active ANTX Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Martin Patricia A.	1	—
Aziz Kabeer	1	—
Marks Gilbert Lynn	1	—
Eizen Joshua M	1	$25K
Williams Sarah Joanne	1	$1K

Recent ANTX Form 8-K Material Events

2026-06-08 — Item 5.07 [SEC]
2026-06-04 — Item 7.01, 8.01, 9.01 [SEC]
2026-05-11 — Item 2.02, 9.01 [SEC]
2026-04-09 — Item 8.01, 9.01 · Financing · neutral [SEC]
AN2 Therapeutics entered into an Open Market Sale Agreement (ATM offering) with Jefferies LLC on April 9, 2026, allowing the company to issue and sell up to $80 million of common stock at its discretion through an at-the-market offering on Nasdaq. Jefferies will receive a commiss
2026-03-20 — Item 5.02 · Leadership · neutral [SEC]
AN2 Therapeutics' Board of Directors approved a stock option repricing on March 19, 2026, reducing the exercise price of all outstanding stock options to $3.91 per share (the closing price on the repricing date). The repricing applies to options held by named executive officers a

Recent Insider Filings

2026-07-10 — Aziz Kabeer (Insider)
2026-07-10 — Marks Gilbert Lynn (Insider)
2026-07-10 — Martin Patricia A. (Insider)
2026-07-10 — Eizen Joshua M (See Remarks)
2026-06-02 — Williams Sarah Joanne (Principal Accounting Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ANTX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ANTX Insider Trading — FAQ

What is the latest insider trade for ANTX?: AN2 Therapeutics, Inc. (ANTX) had 5 insider filings in the last 90 days, with the most recent on 2026-07-10. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ANTX stock?: 0 insider purchases of ANTX were filed in the last 90 days.
How many insiders are selling ANTX stock?: 0 insider sales of ANTX were filed in the last 90 days.
Where can I see ANTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ANTX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live ANTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.